Rare complications post intravesical application of Bacillus-Calmette Guérin (BGG) vaccine
Authors:
Alexandra Gregušová; Petr Klézl; Robert Grill
Authors‘ workplace:
Urologická klinika FNKV a 3. LF UK v Praze
Published in:
Ces Urol 2023; 27(1): 36-40
Category:
Case reports
Overview
Introduction: BCG vaccine treatment is the gold standard for high-risk non-muscle invasive urothelial bladder cancer. The most common complications after BCG treatment are hematuria and symptoms of lower urinary tract infection. Rarely, systemic symptoms occur such as fever or BCG sepsis. As of 2020, the vaccine was administered at our department to 66 patients, of which 6 patients had complications that required interruption of instillations. In this article, we report two rare complications of BCG vaccine therapy – BCG sepsis and the development of a tuberculous prostate abscess.
Description of cases: Patient 1 – A 70-year-old patient with a pT1HG bladder tumor developed fever after the 5th dose of the initial course, elevated liver function tests and bilateral lung lesions were present on CT scan. Antituberculosis treatment was started, after which the patient‘s condition improved very slowly.
Patient 2 – A 70-year-old patient with a pT1HG bladder tumor had a post-BCG, PSA level was 8.9 so we performed a MRI of a prostatae, which showed a suspicious PIRADS 4 and 5 lesion. Caseous necrosis was confirmed histologically from the biopsy, the PCR test for M. tuberculosis was positive. The patient is now being treated with antituberculotic drugs.
Conclusion: The most common complications of BCG vaccine treatment are lower urinary tract symptoms (LUTS) and lower urinary tract infections; rarely, systemic complications requiring treatment discontinuation may occur.
Keywords:
tuberculosis – urinary bladder – complications – urothelial cancer – BCG
Sources
1. EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2022. ISBN 978-94-92671-16-5.
2. Brausi M, Oddens J, Sylvester R, et al. Side effects of Bacillus Calmette‑Guerin (BCG) in the treatment of intermediate- and high‑risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito‑urinary cancers group randomised phase 3 study comparing one‑third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014; 65: 69.
3. Witjes JA, Palou J, Soloway M, et al. Clinical practice recommendations for the prevention and management of intravesical therapy‑associated adverse events. Eur Urol Suppl. 2008; 7: 667.
4. van der Meijden AP, Sylvestrer RJ, Oosterlinck W, et al. Maintenance Bacillus Calmette‑Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito‑Urinary Group Phase III Trial. Eur Urol. 2003; 44: 429.
5. Marques M, Vazquez D, Sousa S, et al. Disseminated Bacillus Calmette‑Guérin (BCG) infection with pulmonary and renal involvement: a rare complication of BCG immunotherapy. A case report and narrative review. Pulmonology. 2020; 26(6): 346–352.
Labels
Paediatric urologist Nephrology UrologyArticle was published in
Czech Urology
2023 Issue 1
Most read in this issue
- The WHO Classification of Urinary and Male Genital Tumours 2022: news in the urinary tract neoplasms classification
- Rare thrombosis of pampiniform plexus in a COVID-19 patient – a case report
- Rare complications post intravesical application of Bacillus-Calmette Guérin (BGG) vaccine
- Obesity and risk of prostate cancer